BR9711160A - Composições farmacêuticas para neutralizar danosss a células ou tecido, prcoessos para o tratamento de indivìduo para neutralizar danos a células, tecido ou órgão e para a conservação ex vivo de 'rogão, tecido ou células, e, composto. - Google Patents

Composições farmacêuticas para neutralizar danosss a células ou tecido, prcoessos para o tratamento de indivìduo para neutralizar danos a células, tecido ou órgão e para a conservação ex vivo de 'rogão, tecido ou células, e, composto.

Info

Publication number
BR9711160A
BR9711160A BR9711160-0A BR9711160A BR9711160A BR 9711160 A BR9711160 A BR 9711160A BR 9711160 A BR9711160 A BR 9711160A BR 9711160 A BR9711160 A BR 9711160A
Authority
BR
Brazil
Prior art keywords
tissue
cells
damage
neutralize
organ
Prior art date
Application number
BR9711160-0A
Other languages
English (en)
Inventor
Abraham Novogrodsky
Alexander Levitzki
Aviv Gazit
Original Assignee
Morresearch Applic Ltd
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morresearch Applic Ltd, Yissum Res Dev Co filed Critical Morresearch Applic Ltd
Publication of BR9711160A publication Critical patent/BR9711160A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSIçõES FARMACêUTICAS PARA NEUTRALIZAR DANOS A CéLULAS OU TECIDO, PROCESSOS PARA O TRATAMENTO DE UM INDIVìDUO PARA NEUTRALIZAR DANOS A CéLULAS, TECIDO OU óRGãO E PARA A CONSERVAçãO EX VIVO DE óRGãO, TECIDO OU CéLULAS, E, COMPOSTO". Compostos úteis para neutralizar efeitos tóxicos indesejados em células, tecidos ou órgãos, apresentando a fórmula (I) em que: Ar é um grupo de fórmulas (i) ou (ii), n é O ou, quando Ar tem a fórmula (i), acima, então n também pode ser 1, R é CN, -C(S)NH~ 2~, -C(S)NH~ 2~, -C(O)NHR~ 3~ ou, quando R~ 1~ é 4-NO~ 2~ e R~ 2~ é ou 3-OH, então R também pode ser um grupo de fórmulas (iii), (iv), (v), (vi) em que R~ 3~ é H, fenila, fenila(alquila inferior) ou piridilmetila; R~ 1~ e R~ 2~ são, cada um, independentemente, H, OH, NO~ 2~ ou, quando R é CN, também CH~ 3~, F ou CF~ 3~, desde que ambos, R~ 1~ e R~ 2~, sejam simultaneamente H.
BR9711160-0A 1996-08-14 1997-08-14 Composições farmacêuticas para neutralizar danosss a células ou tecido, prcoessos para o tratamento de indivìduo para neutralizar danos a células, tecido ou órgão e para a conservação ex vivo de 'rogão, tecido ou células, e, composto. BR9711160A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11906996A IL119069A0 (en) 1996-08-14 1996-08-14 Pharmaceutical composition comprising tyrphostins
PCT/IL1997/000276 WO1998006391A1 (en) 1996-08-14 1997-08-14 Pharmaceutical compositions comprising tyrphostins

Publications (1)

Publication Number Publication Date
BR9711160A true BR9711160A (pt) 2000-01-11

Family

ID=11069189

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9711160-0A BR9711160A (pt) 1996-08-14 1997-08-14 Composições farmacêuticas para neutralizar danosss a células ou tecido, prcoessos para o tratamento de indivìduo para neutralizar danos a células, tecido ou órgão e para a conservação ex vivo de 'rogão, tecido ou células, e, composto.

Country Status (11)

Country Link
US (2) US6426366B1 (pt)
EP (1) EP0923371B1 (pt)
JP (1) JP2001504085A (pt)
CN (1) CN1232392A (pt)
AT (1) ATE266398T1 (pt)
AU (1) AU728672B2 (pt)
BR (1) BR9711160A (pt)
CA (1) CA2263325A1 (pt)
DE (1) DE69729104D1 (pt)
IL (1) IL119069A0 (pt)
WO (1) WO1998006391A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003525862A (ja) * 1999-01-27 2003-09-02 ザ ユニヴァーシティー オブ サウス フロリダ ヒト癌の治療のためのｓｔａｔ３シグナル伝達の阻害
ATE462423T1 (de) * 1999-10-12 2010-04-15 Univ Temple Ungesättigte arylsulfone zum schutz von normalen zellen gegen die zytotoxische wirkung von chemotherapeutika
US20040052762A1 (en) * 2001-09-10 2004-03-18 Hua Yu Stat3 agonists and antagonists and therapeutic uses thereof
WO2003065971A2 (en) * 2001-06-14 2003-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Non-myeloablative tolerogenic treatment with tyrphostins
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
US7638122B2 (en) * 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
EP1701941B1 (en) * 2003-12-11 2012-05-30 Board of Regents, The University of Texas System Compounds for treatment of cell proliferative diseases
EP1737493B1 (en) * 2004-02-25 2011-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of insulin-like growth factor receptor -1 for inhibiting tumor cell growth
RU2456265C2 (ru) * 2006-03-31 2012-07-20 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Биологически доступная для перорального применения кофейная кислота, относящаяся к противоопухолевым лекарственным средствам
US20100292229A1 (en) * 2006-06-30 2010-11-18 The Board Of Regents Of The University Of Texas System Tryphostin-analogs for the treatment of cell proliferative diseases
EP2282739A2 (en) * 2008-05-05 2011-02-16 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer
KR20110033922A (ko) 2008-07-08 2011-04-01 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 전사의 신호 변환자 및 활성제（ｓｔａｔｓ）의 증식 및 활성화의 신규한 억제제
WO2011080261A1 (en) 2009-12-28 2011-07-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for improved cardiomyogenic differentiation of pluripotent cells
AU2018366270B2 (en) 2017-11-10 2023-04-20 Board Of Regents, The University Of Texas System Caffeic acid derivatives for treating hyperproliferative diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH484603A (de) 1966-03-21 1970-01-31 Ciba Geigy Schädlingsbekämpfungsmittel, enthaltend bestimmte Malodinitrile
US3551573A (en) 1967-11-08 1970-12-29 Monsanto Co Insecticidal composition and method containing anilinomethylene malonitriles
US3726662A (en) * 1970-01-14 1973-04-10 Monsanto Co Herbicidal anilinomethylene-malononitriles
NL7800191A (nl) * 1977-01-10 1978-07-12 Ciba Geigy Anthelmintisch preparaat.
AU632992B2 (en) * 1987-12-24 1993-01-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Pharmaceutical compositions comprising benzylidene- and cinnamylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation
RU2024514C1 (ru) 1991-10-01 1994-12-15 Иркутский институт органической химии СО РАН Комплекс 1-этилимидазола с аскорбатом цинка, повышающий устойчивость организма к действию диоксида азота и обладающий цитопротекторным и антигипоксическим действием
US5284868A (en) * 1991-10-09 1994-02-08 Eli Lilly And Company Pharmaceutical compounds
US5972598A (en) * 1992-09-17 1999-10-26 Board Of Trustess Of The University Of Illinois Methods for preventing multidrug resistance in cancer cells
KR960703622A (ko) 1993-07-15 1996-08-31 수잔 포오덴 단백질 티로신 키나아제 억제제의 프로드러그(prodrugs of protein tyrosine kinase inhibitors)
IL107736A (en) * 1993-11-24 2001-01-11 Yissum Res Dev Co Pharmaceutical composition for the prevention of septic shock and for the treatment of chronic inflammatory diseases
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
WO1995024190A2 (en) * 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
DE69634900T2 (de) * 1995-09-11 2006-05-18 Osteoarthritis Sciences, Inc., Cambridge Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis

Also Published As

Publication number Publication date
US20030013748A1 (en) 2003-01-16
US6426366B1 (en) 2002-07-30
WO1998006391A1 (en) 1998-02-19
ATE266398T1 (de) 2004-05-15
AU3782297A (en) 1998-03-06
DE69729104D1 (de) 2004-06-17
EP0923371B1 (en) 2004-05-12
CA2263325A1 (en) 1998-02-19
EP0923371A1 (en) 1999-06-23
CN1232392A (zh) 1999-10-20
AU728672B2 (en) 2001-01-18
IL119069A0 (en) 1996-11-14
JP2001504085A (ja) 2001-03-27

Similar Documents

Publication Publication Date Title
BR9711160A (pt) Composições farmacêuticas para neutralizar danosss a células ou tecido, prcoessos para o tratamento de indivìduo para neutralizar danos a células, tecido ou órgão e para a conservação ex vivo de 'rogão, tecido ou células, e, composto.
JP3819765B2 (ja) ふけ形成抑制効果を有する毛髪化粧料組成物
ATE334985T1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
DE60130023D1 (de) Behandlung der nebenwirkungen von statinen
ATE252529T1 (de) Colchinolderivate als gefässschädigende mittel
BR0113757A (pt) Derivados de quinolinona como inibibores de tirosina quinase
FR2662701B1 (fr) Composition tinctoriale a base de 5,6-dihydroxyindolines et procede de teinture des fibres keratiniques.
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
DE60213404D1 (de) Verwendung von sulodexid zur behandlung von reizdarm
BRPI0620664B1 (pt) processo cosmético não terapêutico para despigmentar e/ou clarear uma pele, composição cosmética ou dermatológica e uso de um composto de fórmula (i)
NO20072089L (no) Benzimidazolderivater, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav
ATE172117T1 (de) Verwendung von trospiumchlorid zur herstellung eines arzneimittels zur behandlung von blasenkrankheiten
TR200103550T2 (tr) Faktör VIIa inhibitörler.
DE60026883D1 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
DE69822626D1 (de) Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
NO20093371L (no) Bis-(N,N'-bis(2-halogenetyl)amino)fosforamidater som antitumormiddel
US4464397A (en) Derivatives of lysine and aspartic acid
ATE274513T1 (de) Verbindungen und verfahren zur behandlung von schmerz
DE69629282D1 (de) Verwendung eines pyruvatdehydrogenaseaktivators zur behandlung der ischämie in gliedern
EA200000762A1 (ru) Способ для консервации органов или других тканей для трансплантации
CO5170445A1 (es) Nuevos compuestos morfinoides,su preparacion y utilizacion
KR20090099163A (ko) 블랙 머드를 함유하는 샴푸 조성물
KR100340086B1 (ko) 비듬방지용 샴푸조성물
ATE423564T1 (de) Zusammensetzung für die kosmetische behandlung von altersbedingten dermatologischen symptomen
TH23455A (th) สารผสมสำหรับทำความสะอาดผิวหนัง

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: NOTOX LTD. (IL)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.